Clinical trial NCT01723475: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
Official title: An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Prostatic Neoplasms
Keywords: Phase I
Dose Escalation
Prostate cancer
Antibodies
Bispecific T-cell Engager (BiTE)
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2012-11-08
Enrollment: 47
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is the first study where BAY2010112 is given to humans. Patients with castration resistant prostate cancer will be treated. Every patient will receive drug treatment, there is no placebo group. Patients will receive different dosages of BAY2010112 to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY2010112.

The study will also assess the pharmacokinetics and the clinical efficacy of BAY2010112.

BAY2010112 will be given daily as subcutaneous injection or as continuous intravenous infusion. Treatment will be stopped if the tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the patient decides to exit treatment.


Eligibility criteria: Inclusion Criteria:

* Male subjects, aged \>/= 18 years
* Subjects with histologically or cytologically proven advanced castration-resistant prostate cancer (CRPC)

  * who failed at least 1 taxane regimen and are refractory to abiraterone and/or enzalutamide therapy OR
  * who have actively refused any treatment which would be regarded standard.
* Subjects should have undergone bilateral orchiectomy or should be on continuous androgen deprivation therapy with a gonadotropin releasing hormone agonist or antagonist.
* Subjects must have shown progressive disease after discontinuation of anti-androgen therapy (i.e. flutamide, bicalutamide or nilutamide) before study drug treatment.
* Total serum testosterone should be less than 50 ng/ml or 1.7 nmol/L
* Evidence of progressive disease, defined as one or more (Prostate Cancer Working Group 2 (PCWG2) criteria):
* PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart
* Nodal (in lymph nodes \>/= 2cm) or visceral progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
* Appearance of one more new lesions in bone scan
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
* Life expectancy of at least 3 months

Exclusion Criteria:

* Any anticancer therapy or immunotherapy within 4 weeks of start of first dose
* Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy
* Prior radiotherapy (local palliative radiotherapy is permitted)
* History of allergic reactions to monoclonal antibody therapy
* History of clinical significant cardiac disease: including unstable angina, acute myocardial infarction within 6 months prior to first study treatment, congestive heart failure ≥New York Heart Association (NYHA) Class III), and arrhythmia requiring therapy except for beta-blockers, calcium channel blockers and digoxin or uncontrolled hypertension, despite optimal medical management
* Clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QT interval corrected for heart rate (QTc)-interval over 450 msec
* Current evidence or history of uncured (i.a. any absolute risk of latent infection) of hepatitis B or C or human immunodeficiency virus (HIV) infection
* Chronic systemic corticosteroid therapy or any other immunosuppressive therapies should have been stopped at screening start
* Seizure disorder requiring therapy (such as steroids or anti-epileptics)
* Subjects unable to inject the study drug subcutaneously for intended s.c. application
* Non-suitable for a central venous access for intended c.i.v. administration

Primary outcomes:
measure: Number of participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: Up to 2 years or longer if indicated
measure: Maximum Tolerated Dose (MTD)
timeFrame: Up to 2 years or longer if indicated
Secondary outcomes:
measure: Maximum drug concentration (Cmax) of BAY2010112 in serum after single and multiple doses administration
timeFrame: Cycle 1 Day1 and 15; (1 Cycle is 21 days long)
measure: Area under the concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY2010112
timeFrame: Cycle 1 (1 Cycle is 21 days long)
measure: Tumor response
timeFrame: Up to 2 years or longer if indicated
measure: Prostate-specific antigen (PSA) response
timeFrame: Up to 2 years or longer if indicated
Other outcomes:
Locations:
city: Linz
country: Austria
state: Oberösterreich
city: Wien
country: Austria
city: Heidelberg
country: Germany
state: Baden-Württemberg
city: Würzburg
country: Germany
state: Bayern
city: Berlin
country: Germany
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
citation: Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25.
citation: Hummel HD, Kufer P, Grullich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Docke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Pasotuxizumab, a BiTE(R) immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10.